MiR-3606-3p inhibits systemic sclerosis through targeting TGF-β type II receptor

References

• LeRoy EC, Black C, Fleischmajer R, et al. Systemic sclerosis: classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–205.
   PubMed Web of Science ®Google Scholar
• Kawakami T, Ihn H, Xu W, et al. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol. 1998;110:47–51.
   PubMed Web of Science ®Google Scholar
• Garret SM, Frost DB, Feghali-Bostwick C. The mighty fibroblast and its utility in scleroderma research. J Scleroderma Related Disord. 2017;2:69–134.
   PubMed Web of Science ®Google Scholar
• Shreiner AB, Murray C, Denton C, et al. Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Related Disord. 2016;1:247–256.
   PubMed Web of Science ®Google Scholar
• Baraut J, Farge D, Jean-Louis F, et al. Transforming growth factor-beta increases interleukin-13 synthesis via GATA-3 transcription factor in T-lymphocytes from patients with systemic sclerosis. Arthritis Res Ther. 2015;17:196.
   PubMed Web of Science ®Google Scholar
• Derk CT. Transforming growth factor-beta (TGF-beta) and its role in the pathogenesis of systemic sclerosis: a novel target for therapy? Recent Pat Inflamm Allergy Drug Discov. 2007;1:142–145.
   PubMedGoogle Scholar
• Wu T, Chu H, Tu W, et al. Dissection of the mechanism of traditional Chinese medical prescription-Yiqihuoxue formula as an effective anti-fibrotic treatment for systemic sclerosis. BMC Complement Altern Med. 2014;14:224.
   PubMed Web of Science ®Google Scholar
• La J, Reed E, Chan L, et al. Downregulation of TGF-beta receptor-2 expression and signaling through inhibition of Na/K-ATPase. PloS one. 2016;11:e0168363.
   PubMed Web of Science ®Google Scholar
• Phan TT, Lim IJ, Aalami O, et al. Smad3 signalling plays an important role in keloid pathogenesis via epithelial-mesenchymal interactions. J Pathol. 2005;207:232–242.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ye H, Xiang F, et al. miR-18a-5p inhibits sub-pleural pulmonary fibrosis by targeting TGF-beta receptor II. Mol Therapy. 2017;25:728–738.
   PubMed Web of Science ®Google Scholar
• Fierro-Fernandez M, Busnadiego O, Sandoval P, et al. miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2. EMBO Rep. 2015;16:1358–1377.
   PubMed Web of Science ®Google Scholar
• Li M, Krishnaveni MS, Li C, et al. Epithelium-specific deletion of TGF-beta receptor type II protects mice from bleomycin-induced pulmonary fibrosis. J Clin Invest. 2011;121:277–287.
   PubMed Web of Science ®Google Scholar
• Miguel V, Busnadiego O, Fierro-Fernandez M, et al. Protective role for miR-9-5p in the fibrogenic transformation of human dermal fibroblasts. Fibrogenesis Tissue Repair. 2016;9:7.
   PubMed Web of Science ®Google Scholar
• Meng J, Li L, Zhao Y, et al. MicroRNA-196a/b mitigate renal fibrosis by targeting TGF-beta receptor 2. J Am Soc Nephrology. 2016;27:3006–3021.
   PubMed Web of Science ®Google Scholar
• Yu F, Chen B, Fan X, et al. Epigenetically-regulated MicroRNA-9-5p Suppresses the activation of hepatic stellate cells via TGFBR1 and TGFBR2. Cel Physiol Biochem. 2017;43:2242–2252.
   PubMed Web of Science ®Google Scholar
• De Oliveira FL, Araujo-Jorge TC, De Souza EM, et al. Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in Chagas disease. PLoS Negl Trop Dis. 2012;6:e1696.
   PubMed Web of Science ®Google Scholar
• Asano Y, Ihn H, Yamane K, et al. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest. 2004;113:253–264.
   PubMed Web of Science ®Google Scholar
• Pannu J, Gore-Hyer E, Yamanaka M, et al. An increased transforming growth factor beta receptor type I: typeII ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma. Arthritis Rheum. 2004;50:1566–1577.
   PubMedGoogle Scholar
• Dong C, Zhu S, Wang T, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proceedings of the National Academy of Sciences of the United States of America 2002; 99:3908–3913.
   Google Scholar
• Shi X, Zhan L, Xiao C, et al. miR-1238 inhibits cell proliferation by targeting LHX2 in non-small cell lung cancer. Oncotarget. 2015;6:19043–19054.
   PubMedGoogle Scholar
• Makino K, Jinnin M, Kajihara I, et al. Circulating miR-142-3p levels in patients with systemic sclerosis. Clin Exp Dermatol. 2012;37:34–39.
   PubMed Web of Science ®Google Scholar
• Makino K, Jinnin M, Hirano A, et al. The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma. J Immunology. 2013;190:3905–3915.
   PubMed Web of Science ®Google Scholar
• Honda N, Jinnin M, Kajihara I, et al. TGF-beta-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts. J Immunology. 2012;188:3323–3331.
   PubMed Web of Science ®Google Scholar
• Li H, Yang R, Fan X, et al. MicroRNA array analysis of microRNAs related to systemic scleroderma. Rheumatol Int. 2012;32:307–313.
   PubMed Web of Science ®Google Scholar
• Honda N, Jinnin M, Kira-Etoh T, et al. miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin beta3. Am J Pathol. 2013;182:206–216.
   PubMed Web of Science ®Google Scholar
• Makino K, Jinnin M, Aoi J, et al. Discoidin domain receptor 2-microRNA 196a-mediated negative feedback against excess type I collagen expression is impaired in scleroderma dermal fibroblasts. J Invest Dermatol. 2013;133:110–119.
   PubMed Web of Science ®Google Scholar
• Chu H, Wu T, Wu W, et al. Involvement of collagen-binding heat shock protein 47 in scleroderma-associated fibrosis. Protein Cell. 2015;6:589–598.
   PubMed Web of Science ®Google Scholar
• Lu J, Liu Q, Wang L, et al. Increased expression of latent TGF-beta-binding protein 4 affects the fibrotic process in scleroderma by TGF-beta/SMAD signaling. Lab Invest. 2017;97:591–601.
   PubMed Web of Science ®Google Scholar
• Shirdel EA, Xie W, Mak TW, et al. NAViGaTing the micronome–using multiple microRNA prediction databases to identify signalling pathway-associated microRNAs. PloS one. 2011;6:e17429.
   PubMed Web of Science ®Google Scholar
• Peoples C, Medsger TA Jr., Lucas M, et al. Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes. J Scleroderma Related Disord. 2016;1:177–240.
   PubMed Web of Science ®Google Scholar
• Pattanaik D, Brown M, Postlethwaite BC, et al. Pathogenesis of systemic sclerosis. Front Immunol. 2015;6:272.
   PubMed Web of Science ®Google Scholar
• Chu H, Shi Y, Jiang S, et al. Treatment effects of the traditional Chinese medicine Shenks in bleomycin-induced lung fibrosis through regulation of TGF-beta/Smad3 signaling and oxidative stress. Sci Rep. 2017;7:2252.
   PubMed Web of Science ®Google Scholar
• Liu Q, Chu H, Ma Y, et al. Salvianolic acid B attenuates experimental pulmonary fibrosis through inhibition of the TGF-beta signaling pathway. Sci Rep. 2016;6:27610.
   PubMed Web of Science ®Google Scholar
• Chu H, Jiang S, Liu Q, et al. Sirtuin1 protects against systemic sclerosis-related pulmonary fibrosis by decreasing proinflammatory and profibrotic processes. Am J Respir Cell Mol Biol. 2018;58:28–39.
   PubMed Web of Science ®Google Scholar
• Wang JC, Lai S, Guo X, et al. Attenuation of fibrosis in vitro and in vivo with SPARC siRNA. Arthritis Res Ther. 2010;12:R60.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Alexander PB, Wang XF. TGF-beta family signaling in the control of cell proliferation and survival. In: Cold spring harbor perspectives in biology. 2017. p. 9.
   Google Scholar
• Lei Z, Xu G, Wang L, et al. MiR-142-3p represses TGF-beta-induced growth inhibition through repression of TGFbetaR1 in non-small cell lung cancer. FASEB J. 2014;28:2696–2704.
   PubMed Web of Science ®Google Scholar
• Artlett CM, Sassi-Gaha S, Hope JL, et al. Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis. Arthritis Res Ther. 2017;19:144.
   PubMed Web of Science ®Google Scholar
• Jafarinejad-Farsangi S, Farazmand A, Gharibdoost F, et al. Inhibition of MicroRNA-21 induces apoptosis in dermal fibroblasts of patients with systemic sclerosis. Int J Dermatol. 2016;55:1259–1267.
   PubMed Web of Science ®Google Scholar
• Jiang X, Tsitsiou E, Herrick SE, et al. MicroRNAs and the regulation of fibrosis. FEBS J. 2010;277:2015–2021.
   PubMed Web of Science ®Google Scholar
• Aslani S, Sobhani S, Gharibdoost F, et al. Epigenetics and pathogenesis of systemic sclerosis; the ins and outs. Hum Immunol. 2018;79:178–187.
   PubMed Web of Science ®Google Scholar